Abstract
Recent clinical studies on patients with malignancies, who were treated with UHF and LMWHs raised the possibility, that these agents may possess an inhibitory effect on tumor progression. Further studies supported that this effect is independent from the anticoagulant and antithrombotic action. In this retrospective study oncological patients with an increased risk for thromboembolism were choosen, who received prophylactic treatment with an LMWH (nadroparin) at least for 6 months. Comparing with the control group, in some subgroups (T3 and T4, as well as M1) the LMWH-treated patients showed a significantly increased survival.
Similar content being viewed by others
References
von Delius S, Ayvaz M, Wagenpfeil S et al (2007) Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost 98:434–439
Lazo-Lagner A, Goss GD, Spaans JN et al (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thrombosis Haemostasis 5:729–737
Kakkar AK (2005) Low-molecular-weight heparin and survival in patients with malignant disease. Cancer Control 12:22–30
Akl EA, VanDoormaal FF, Barba M et al (2008) Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res 27:4
Kakkar AK, Levine MN, Kadziola Z (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944–1948
Tóvári J, Bereczky B, Gilly R et al (2004) Effect of heparin treatment on the metastatization of melanoma in a preclinical model (in Hungarian). Magy Onkol 48:235–241
De Lorenzo F, Dotsenko O, Scully MF et al (2006) The Role of Anticoagulation in Cancer Patients: Facts and Figures. Anti-Cancer Agents Med Chem 6:579–587
Klerk CPW, Smorenburg SM, Otten HM et al (2005) The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy. J Clin Oncol 23:2130–2135
Li JP (2008) Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis? Anti-Cancer Agents Med Chem 8:64–76
Falanga A, Marchetti M (2007) Heparin in tumor progression and metastatic dissemination. Semin Thromb Haemost 33:688–694
Castelli R, Porro F, Tarsia P (2004) The heparins and cancer: review of clinical trials and biological properties. Vasc Med 9:205–213
Vlodavsky I, Ilan N, Nadir Y et al (2007) Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 120:112–120
Casu B, Vlodavsky I, Sanderson RD (2009) Pathophysiol Haemost Thromb 2007-08: 36, 195–203, doi: 10.1159/000175157
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nagy, Z., Turcsik, V. & Blaskó, G. The Effect of LMWH (Nadroparin) on Tumor Progression. Pathol. Oncol. Res. 15, 689–692 (2009). https://doi.org/10.1007/s12253-009-9204-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-009-9204-7